It was reported that the CHEK2 mutation was seen in 73 of 468 (15.6%) unselected patients with papillary thyroid cancer, compared to 28 of 460 (6.0%) age—and sex-matched controls (OR 3.3; p < 0.0001) [17]. This evidence concerns the gene CHEK2 and thyroid gland papillary carcinoma.